Merck
Provides life science materials and technologies including bioinks and 3D printing solutions for pharmaceutical and bioprinting applications, enabling personalized medicine and drug development.
- CEO / Founder
- Kai Beckmann (Chair of the Executive Board and Group CEO)
- Team Size
- 10000+
- Stage
- Public
- Total Funding
- Publicly Traded
- Latest Round
- IPO
- Key Investors
- E. Merck KG (majority owner via general partners, ~70% of total capital); free-float public shareholders (~30%)
Technology & Products
Key Products
Life Science products (e.g., bioinks, cell culture media, lab water systems), Healthcare products (e.g., oncology, neurology, fertility drugs), Electronics materials (e.g., OLED materials, semiconductor solutions).
Technological Advantage
Proprietary materials and processes for bioprinting and pharmaceutical 3D printing, supported by a global R&D network and regulatory expertise in GMP standards.
Patent position
Merck filed 9 patent families in 2022-2024, up 29% from 7 in 2019-2021, even as tracked AM filings in the same patent offices fell 16%, indicating Merck is bucking the broader decline. AMPulse analysis
- Filing momentum
- 9 families filed 2022–2024, 7 in 2019–2021 (+29%); all tracked AM filings in the same offices -16%
- Filed in
- WO 46%EP 39%US 36%CN 18%JP 7%
28 AM patent families in total. Recent years are still being published, so read a filing change against the same-office figure.
Differentiation
Value Proposition
Accelerates drug development and bioprinting research through high-quality materials and integrated 3D printing technologies, reducing time-to-market for therapies and enabling customized formulations.
How They Differentiate
Merck KGaA differentiates itself through its diversified business model spanning Healthcare, Life Science, and Electronics, allowing for integrated solutions and cross-sector innovation. Its extensive portfolio, strong R&D focus, and commitment to sustainability further distinguish it from competitors.
Market & Competition
Target Customers
Pharmaceutical companies, research institutions, biotech firms, and academic labs
Industry Verticals
Pharmaceutical; Biotechnology; Medical Research; Healthcare
Competitors
Johnson & Johnson, Roche, AstraZeneca, Novartis, Sanofi, Bayer, Thermo Fisher Scientific, Danaher, Sartorius.
Growth & Milestones
Growth Metrics
Full-year 2025: Group net sales supported by Life Science €9.0bn (organic +4.0%), with Process Solutions delivering ~10% organic growth for four consecutive quarters; Healthcare €8.6bn (organic +3.7%). Full-year 2024 Group sales €21.2bn (organic +2.0%); Life Science 2024 organic −3.3% before recovery.
Major Milestones
2015: Merger of Merck Millipore and Sigma-Aldrich; 2020: Partnership with AMCM for 3D-printed tablets; Establishment of 3D Technologies (3DT) organization; Mar 2025: Khadija Ben Hammada joins Executive Board as CPO; May 1, 2026: Kai Beckmann succeeds Belén Garijo as Chair of the Executive Board and Group CEO
Notable Customers
Research institutions and pharmaceutical companies using Merck's bioprinting solutions include Harvard University, MIT, Johnson & Johnson, and Roche, as referenced in case studies and collaborations for drug development and tissue engineering applications.
AM patents
AM-relevant patents linked to this company.
- Patents
- 43
- Granted
- 8
- Families
- 28
Leading domains: process (43), application (29), equipment (16)
Filings by year: 2024: 3 · 2023: 4 · 2022: 5 · 2021: 4 · 2020: 1 · 2019: 5
- PROCESS FOR THE MANUFACTURE OF A SOLID PHARMACEUTICAL ADMINSTRATION FORM2018046642 · WO
- METHOD FOR ADDITIVE MANUFACTURING OF A 3D ITEM BY MEANS OF FUSED DEPOSITION MODELING AND ADDITIVE MANUFACTURING APPARATUS2025214922 · WO
- PROCESS FOR PRODUCING MOULDED BODIES WITH A PREDETERMINED PORE STRUCTURE00627983 · EP
- コーティングされた固形医薬投薬形態の調製のためのプロセス34500282|2022500282 · JP
- METHOD FOR ADDITIVE MANUFACTURE OF A PRODUCT, MANUFACTURING DEVICE AND SOLID PHARMACEUTICAL DOSAGE FORM04013602 · EP